Obesity
Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
As new weight loss medications garnered buzz last year, analysts’ forecasts signaled these drugs would be blockbusters, with some of the highest estimates calling for peak sales of at least $100 billion. In recent days, the expectations are moving higher still. The initial projections were made before Wall Street saw the results of Novo Nordisk’s […]
Read More
Wager in opposition to America’s enjoy for junk food stuff? Morgan Stanley sees hard periods forward for snack stocks like Hostess
J.M. Smucker ‘s prepare to obtain Twinkies -maker Hostess Models is a risky shift, if Morgan Stanley’s most current investigate is appropriate. The company revisited its August call that a new course of body weight loss medicines would hamper expansion at some foodstuff and beverage firms . This time it backed up its thesis with […]
Read More
Ozempic, Wegovy may curb drinking, smoking and other addictive behaviors – here’s what we know
An Ozempic (semaglutide) injection pen is seen on a kitchen table in Riga, Latvia on 06 August, 2023. Jaap Arriens | Nurphoto | Getty Images Heather Le Biller shed 9 pounds within the first week of taking Novo Nordisk‘s blockbuster diabetes drug Ozempic – and then even more as she continued treatment. Le Biller, a […]
Read More
Big pharma’s blockbuster obesity drug battle is just getting started, and it’s headed for $100 billion
Ozempic drug to treat diabetes. Courtesy: Ozempic In their most recent earnings reports, Novo Nordisk and Eli Lilly proved why they are the undisputed heavyweights in the prizefight for control of the rapidly growing weight-loss medications market. Beyond staggering sales figures for Novo’s Ozempic and Wegovy and Lilly’s Mounjaro, news of a study showing Wegovy […]
Read More
Obesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buying
Industry analysts are insisting that new weight loss and diabetes drugs like Ozempic won’t hurt the demand for insulin pumps and continuous glucose monitors, but most investors aren’t buying it. Medical device stocks have been falling session after session, prompting UBS analyst Danielle Antalffy on Wednesday to lower her price targets for Dexcom and a […]
Read More
Your boarding go and body weight, you should: Why airways are asking passengers to move on the scales
Commencing Monday, passengers traveling on Korean Air may well be questioned to phase on a scale in advance of boarding their flight. The exercising, which will last about a few months, is essential by regulation and applies to all Korean flag carriers, a Korean Air agent advised CNBC. The legislation involves airlines to weigh travellers […]
Read More
Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion
Liselotte Sabroe | Afp | Getty Images Novo Nordisk on Thursday said it will acquire Inversago Pharma, a privately held obesity drug maker, for up to $1.08 billion to broaden the Danish company’s blockbuster weight loss portfolio. The deal is Novo Nordisk’s latest attempt to capitalize on the weight loss industry gold rush, which began […]
Read More
Insurers face long road, high cost to cover obesity drugs after promising Wegovy heart health data
A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. Jim Vondruska | Reuters Novo Nordisk‘s obesity drug Wegovy slashed the risk of serious heart problems by 20% in a large clinical trial – a landmark finding that could put more […]
Read More
Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%
Sopa Images | Lightrocket | Getty Images Eli Lilly on Tuesday raised its full-year guidance as second-quarter profit jumped 85% from the same period a year ago on strong sales from the pharmaceutical giant’s drug pipeline. The company now expects full-year revenue of between $33.4 billion to $33.9 billion, up from a previous forecast of […]
Read More
Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials
The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, September 17, 2020. Mike Blake | Reuters An Eli Lilly experimental drug helped patients lose about 26% of their weight on average following extended use or intensive lifestyle changes, according to results from two studies released Thursday. It’s the […]
Read More